← All candidates
39 insider filings on record.
39 filings on record.
GLUEMonte Rosa Therapeutics, Inc.
NasdaqGS · Healthcare · $1.32B
$14.27
-2.62% today
39 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 20 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.32B
Float
54.0M
64% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
30.7
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
34 more transactions on Pro →Context
Wall St
$28.50 avg target
+99.7% vs today · 6 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 4 quarters beat
Q2 '26−$0.43 act−$0.06
Q1 '26−$0.45 act−$0.07
Q4 '25−$0.55 act−$0.21
Q3 '25−$0.33 act+$0.02
Coverage
Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M MilestoneInsider Monkey · 3d agoMonte Rosa Therapeutics (GLUE) Is Down 30.7% After Deepening Q2 Losses And H1 Earnings ReversalSimply Wall St. · 08-07Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue EstimatesZacks · 08-06BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?Stocktwits · 07-31
The file stays open
39 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice